JAMA Oncol: New Indiana University study, ctDNA and CTC combined to predict breast cancer recurrence more accurately

!----: Breast cancer is often referred to as the "pink killer", the incidence of female malignant tumors ranked firstin China, the incidence of breast cancer is increasing year by year, more than 300,000 women are diagnosed with breast cancer every yearbreast cancer has a high probability of recurrence, about 30%, therefore, the detection of breast cancer recurrence is also particularly importantA combination of measured circulating tumor DNA (cfDNA) and circulating tumor cells (CTC) can detect diseases that remain in patients with triple-negative breast cancer (TNBC) after new complementary chemotherapy and predict breast cancer recurrence, according to a new studythe team, led by Indiana University, wrote in a July 9 report in the journal JAMA Oncology that because the molecular and cellular signals are independently related to disease recurrence and "exceed standard clinical parameters," this could be an important stratification tool for future post-treatment trialspatients with early three-negative breast cancer often receive new complementary chemotherapy because of the higher risk of recurrence and death of triple-negative breast cancersome patients continue to survive without relapse, but a significant number of patients relapse after chemotherapyblood-based genomic tests, or liquid biopsies, quickly became popular on TNBC and other cancer patients to determine which patients may have residual cancer and which patients may have a prognosis that may be improved by new or existing treatmentsthe abstract liquid biopsy microresidual lesions (MRD) testing recent studies have focused on circulating tumor DNA, including previous research in Indiana, but researchers at the new JAMA Oncology Institute say that because there is evidence that CTCs can be detected in some patients with no signs of ctDNA, adding a second analysis can help enhance the receipt of MRD signalsearly researchers' report describes a pre-planned secondary analysis of 196 female patients in the recently completed randomized clinical trial BRE12-158, which performed new genomic-directed complementary therapy for TNBC patientsresearchers discussed some of the findings at the San Antonio Breast Cancer Symposium last December, but shared them in more detail in a new paper this weekthe researchers analyzed ctDNA and counted the ctDNA using blood samples from patients who received standard new auxiliary treatment, liquid biopsy using basic medicine, and epCAM-based positive selection microfluidic control devicesctCs detected in 142 patients, CTCs, ctDNA and CTCs significantly reduced disease-free and total survival ratesas seen in other studies, ctDNA itself is significantly associated with poor disease-free survivalresearchers said that although CTC-positive patients also had a poor prognosis, the results were not statistically significanthowever, there is a significant correlation between an increase in CTC count and an increase in survival rates there was no significant correlation between CTC-positive and ctDNA positives in 112 patients with both ctDNA and CTC results in other words, one of the patients was positive and the other did not , therefore, when considering both markers at the same time, the sensitivity of the detection of recurrence sourcing in the queue was highest: MRD sensitivity with ctDNA alone was 79%, MRD sensitivity with CTCs alone was 62%, and 90% when used jointly had significantly lower distance disease-free survival rates in ctDNA-positive and CTC-positive patients than in patients with double negatives at 24 months, the incidence of dFS was 52% in patients who were positive for both biomarkers, compared with 89% for negative patients similar trends have been observed in the in non-distant DFS and total survival rates researchers stress that the findings do not yet support the use of liquid biopsy MRD to guide routine clinical practice, as there is no evidence that early detection of residual diseases can alter treatment and thus improve patient semost but they believe the data will be sufficient to support the immediate use of their MRD strategy in clinical trials after the new assisted treatment, which will help to further collect the evidence concept is at the heart of the current planned PERSEVERE trial of BRE12-158, in which ctDNA-positive TNBC patients will receive targeted formulations that match the results of their plasma ct DNA sequencing